logo
Plus   Neg
Share
Email

Genentech Reports RG7716 Phase II Data With Encouraging Results - Quick Facts

Genentech, a member of the Roche Group (RHHBY), reported encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema (DME), treatment with intravitreal RG7716 demonstrated clinically meaningful visual acuity gains from baseline, and statistically significant improvements in visual acuity compared with ranibizumab. The company said the key secondary and exploratory anatomical outcomes - reduction of central retina thickness and improvements in diabetic retinopathy severity scores - were supportive of the primary outcome.

RG7716 is the first bispecific, monoclonal antibody specifically designed for the eye that simultaneously binds to and inactivates vascular endothelial growth factor A and Angiopoietin-2. The company will present data from all Phase II studies at upcoming medical meetings, and plans to discuss its Phase III program with the U.S. FDA following data assessment.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT